Summary.-In order to determine the mechanisms of relapse following response to endocrine therapy, we have measured the oestrogen receptor (RE) content of biopsies of breast cancer in patients receiving various types of endocrine treatment.
endocrine therapy.
No relationship could be found between RE content and plasma gonadotrophin or steroid-hormone concentration, but the fall in RE content correlated with reduced numbers of tumour cells in the biopsy.
These results indicate that relapse following successful endocrine therapy in breast cancer does not appear to be due to the emergence of RE-negative tumour cells. The fall in RE content during response to endocrine therapy may be due to reduced tumour-cell content of the biopsy.
IT IS WELL established that the presence of an oestrogen receptor (RE) in a breast cancer is almost obligatory for response to endocrine therapy (McGuire et al., 1975) . Patients who respond to therapy all eventually relapse, however, but the reason for relapse is not clear.
In an attempt to determine the mechanism of regression and relapse some studies have been carried out in which changes of receptor content of regressing tumours have been measured. These studies indicate that the receptor content of regressing tumours fall in both rodent mammary tumours (Arafah et al., 1980;  Cho-Chung et al., 1978; Bodwin et al., 1978) and human breast carcinomas (Allegra et al., 1980; Namer et al., 1980 Patients. Twenty-six patients (ages 34-94; mean age 67) with skin metastases, extensive local disease or local recurrent breast carcinoma had skin biopsies performed before receiving endocrine therapy, and 2-3 months later, while receiving endocrine therapy. In addition, a group of 13 patients who had relapsed following a previous response to endocrine therapy, had skin biopsies performed. Biopsies taken at relapse were obtained when the treatment was stopped (3 patients) or 2-6 weeks after therapy was discontinued in the remaining patients. Ten of these patients then received further endocrine therapy.
About 0-5 g tissue was removed under lignocaine local anaesthesia and 0 4 g frozen in liquid N2 and stored for subsequent RE and progesterone receptor (RP) estimations. The remaining 0-1 g was examined histologically after fixation in the standard fashion.
Histology.-Histological examination was carried out on 50 skin nodules from 25 patients, where at least 2 skin nodule biopsies (i.e. pre-and on treatment) were available. As the cellularity varied from patient to patient and, of course, between the pairs of samples from the same patient, a quantitative scale was devised: +, small number of single cells scattered in the stroma; +++, confluent sheets of malignant cells occupying most of section. Anything between these two extremes was scored as + +. All sections were routinely stained with haematoxylin and eosin. Some sections were additionally stained for epithelial membrane antigen (EMA), (Sloane & Ormerod, 1981) (1977) .
Hormone-receptor assays.-Receptor assays were performed using the dextran-coatedcharcoal method to separate "bound" from "free" hormone (McGuire et al., 1975) . Binding data were analysed by the method of Scatchard (1949) . Oestrogen and progesterone receptor levels are expressed as fmol/mg of cytosol protein and intra-assay variation was 10%. The interassay variation was 15%. A concentration of receptor > 10 fmol/mg cytosol protein is regarded as positive.
Endocrine therapy.-Eight patients were treated with tamoxifen (T), 7 with aminoglutethimide (A) (Smith et al., 1978) and 3 with Danazol (D) (Coombes et al., 1980) and 5 with a combination of all 3 (TAD). One patient was treated with premarin, one by withdrawal of premarin, and one by oophorectomy.
In the group of 13 patients who had skin biopsies following relapse after endocrine therapy, 4 had been receiving tamoxifen, 5 aminoglutethimide, 2 premarin and 2 oophorectomy. One patient received the TAD combination. Endocrine therapy had been stopped 2-6 weeks before the skin biopsy in 11 cases, and 2 patients were still receiving therapy. One patient who had relapsed after response to tamoxifen responded to further treatment with aminoglutethimide, and had a further skin biopsy when she relapsed on this therapy.
Response criteria.-Response was assessed according to UICC criteria (Hayward et at., 1977) with clinical measurement and photography of the skin lesions, and by appropriate investigations to determine response, or nonresponse at other sites of disease.
(i) Complete response (CR) was defined as disappearance of all clinical and radiological disease for at least one month. (ii) Partial response (PR) was defined as >50% reduction in the product of the Table I ). Receptor content of recurrent skin metastases after response to endocrine therapy (Table   III) Skin biopsies were obtained from 13 patients when they relapsed after responding to a variety of endocrine agents, with one patient being studied on 2 separate occasions. Six of these patients have been included in the responders, and 1 in the non-responders mentioned above. On relapse, 10/14 patients' skin metastases contained measurable RE. One patient, who had been receiving tamoxifen, and whose skin biopsy was RE-at relapse, responded to further therapy with aminoglutethimide. When she relapsed on this treatment, a repeat skin biopsy was RE+ (patient 12; Table III) .
None of the regrowing tumour samples contained measurable progesterone receptor (RP).
Histology
Cellularity of skin nodules, obtained from previously untreated patients, appeared to correlate with RE content (Fig.) All 5 samples graded as + and + + con- Concerning the changes of cellularity during therapy, irrespective of type of endocrine treatment, 8/12 responders showed a decrease whereas of 3/10 nonresponders showed an increase, 4 showed unchanged cellularity, and 3 showed a decrease.
Hormone estimations
Mean values, and standard errors of the means for oestradiol, testosterone, follicle stimulating hormone (FSH), luteinizing hormone (LH) and sex hormone binding globulin (SHBG) taken at the same times as the biopsies from the 26 patients in Tables I and II are shown in Table IV . There was no significant difference between the pre-and post-treatment values for any of these hormones, and no correlation between any individual hormone concentration and RE content.
DISCUSSION
Our results indicate that the tumour RE content is often lowered by successful endocrine therapy, but rises when the tumours regrow. The initial fall in RE content confirms the findings of other investigators (Allegra et al., 1980 , Kiang & Kennedy, 1977 Webster et al., 1978) . These changes in RE content appear to parallel the tumour cellularity of the biopsy material; therefore our observed fall in RE content may be related to the tumour-cell content of the specimen. The fall in RE content did not correlate with Our finding that 10/14 regrowing tumour samples had significant RE indicates that relapse following regression is not usually due to regrowth of a residual REpopulation of tumour cells. We are not certain that all these tumours were RE+ at the start of treatment, but it is widely accepted that only 4-6% of RE-tumours respond to therapy (McGuire et al., 1978) so these tumours were likely to have been initially RE+.
An alternative explanation is that endocrine therapy, for example aminoglutethimide, is no longer capable of suppressing endogenous hormone synthesis, thus allowing endocrine-sensitive tumour cells to regrow. Studies at this institute, however, have shown that patients who respond to aminoglutethimide show adequate steroid suppression, even at relapse (Coombes et al., 1981) .
Many of the patients in the study were receiving tamoxifen, or a combination. Tamoxifen is known to bind RE, and translocate it into the nucleus (Sutherland & Murphy, 1980) and this may explain why many of these patients became REon therapy. Tamoxifen is known to have a long half-life, which has been calculated as 5-3 days (Wilkinson et al., 1980) accounting for the prolonged RE negativity of the tumours biopsied 2-4 weeks after stopping tamoxifen. However, some of the patients not receiving tamoxifen also showed a marked fall in RE.
Since patients often relapse with RE+ tumours, the biochemical changes that have occurred to enable these tumours to regrow in an unfavourable endocrine environment are not clear. A better understanding of these mechanisms could have therapeutic implications for maintenance of endocrine remission.
